We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Biogen Inc. stands sixth on our list among the most ...

UBS analyst Ashwani Verma maintained a Hold rating on Biogen today and set a price target of $130.00. The company’s shares opened today at $133.56. Elevate Your Investing Strate ...

Biogen (($CC:HTER)) announced an update on their ongoing clinical study. Biogen Inc. (BIIB) has announced an update on its ...

In a report released today, Evan Seigerman from BMO Capital maintained a Hold rating on Biogen, with a price target of $128.00. The company’s shares closed yesterday at $134.46. According to TipRanks, ...

Biogen has announced that it has initiated a phase 3 study of investigational felzartamab in adults with primary membranous ...

TMCnet News Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy [June 30, 2025] ...

The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to tacrolimus in adults diagnosed with primary membranous nephropathy (PMN).

In addition to beginning a Phase 3 study of felzartamab in PMN, Biogen also initiated two other Phase 3 studies of felzartamab this year, TRANSCEND (NCT06685757) for late antibody-mediated rejection ...

Biogen acquired the rights to felzartamab, which is already in Phase 3 studies in late antibody-mediated rejection in adult kidney transplant recipients and in IgA nephropathy, as part of last ...